2016-11-14T15:56:27-06:00 2015-12-31 861065772 DELOITTE TAX LLP 655 WEST BROADWAY SUITE 700 SAN DIEGO CA 921018590 990 2015-01-01 330328688 LA JOLLA INSTITUTE FOR ALLERGY & IMMUNOLOGY LAJO 8587526500 9420 ATHENA CIRCLE LA JOLLA CA 920371387 JENNIFER KEYES CFO 8587526500 2016-11-14 1 JOHN SADOFF JR P00540589 6192326500 2015 2017-02-10 21:41:12Z JENNIFER KEYES 9420 ATHENA CIRCLE LA JOLLA CA 920371387 66258650 0 X WWW.LJI.ORG X 1988 CA BIOMEDICAL RESEARCH DEDICATED TO IMPROVING HUMAN HEALTH THROUGH STUDIES OF THE IMMUNE SYSTEM. 21 20 399 129 119265 51782 44790248 55660152 4058346 5213453 45528 -65153 621402 749233 49515524 61557685 0 3000 0 0 26674436 26065694 61725 9405 212870 24910207 26737812 51646368 52815911 -2130844 8741774 27661104 36797526 10083960 10478608 17577144 26318918 X AT LA JOLLA INSTITUTE, OUR SCIENTISTS FOCUS ON UNDERSTANDING HOW THE IMMUNE SYSTEM WORKS IN ORDER TO PROMOTE HUMAN HEALTH AND PREVENT DISEASE. OUR DISCOVERIES APPLY TO MANY DISEASES, RANGING FROM DIABETES TO HEART DISEASE, INFECTIOUS DISEASES TO CANCER. 0 0 46703067 3000 5213453 THE LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY ("LJI") IS A PRIVATE, NONPROFIT MEDICAL RESEARCH ORGANIZATION THAT IS RECOGNIZED AS A WORLD LEADER IN COMPREHENSIVE RESEARCH DEDICATED TO UNDERSTANDING THE INTRICACIES AND POWER OF THE IMMUNE SYSTEM AND APPLYING THAT KNOWLEDGE TOWARD ITS GOAL OF LIFE WITHOUT DISEASE. THE INSTITUTE IS HOME TO 23 INDEPENDENT LABORATORIES, EACH OPERATED BY A LEADING SCIENTIST HANDPICKED FOR HER CREATIVITY AND PIONEERING SPIRIT. EACH OF THESE LABS IS DEDICATED TO UNDERSTANDING THE FAR-REACHING INFLUENCE OF THE IMMUNE SYSTEM AND TO TRAINING TO THE NEXT GENERATION OF SCIENTISTS, TO PROMOTE HUMAN HEALTH AND PREVENT A WIDE RANGE OF DISEASES. THE INSTITUTE WAS RECENTLY RANKED AMONG THE TOP FIVE ORGANIZATIONS WITH THE GREATEST RESEARCH IMPACT IN IMMUNOLOGY WORLDWIDE BY THE RATING AGENCY THOMSON-REUTERS. IN ADDITION, THREE OF ITS SCIENTISTS ARE AMONG THE MOST HIGHLY CITED IMMUNOLOGISTS IN THE WORLD-A DISTINCTION HELD BY LESS THAN HALF OF ONE PERCENT OF ALL PUBLISHING SCIENTISTS. 2015 NOTABLE RESEARCH RESULTSIN 2015, LJI RESEARCH TEAMS MADE DISCOVERIES MERITING PUBLICATION IN LEADING PEER-REVIEWED SCIENTIFIC JOURNALS - 156 PAPERS IN ALL, AN ALMOST 10 PERCENT INCREASE FROM THE YEAR BEFORE. NO FEWER THAN 36 ORIGINAL RESEARCH PAPERS APPEARED IN HIGH IMPACT JOURNALS, WHICH IS A MEASURE OF THE RESEARCH'S PIONEERING NATURE AND INFLUENCE. TOGETHER, THEY ILLUSTRATE THE RANGE AND POWER OF IMMUNOLOGY RESEARCH AND ITS IMPACT ON A BROAD GROUP OF HUMAN HEALTH ISSUES. SOME OF THE HIGHLIGHTS AMONG PAPERS PUBLISHED IN 2015 INCLUDE:THE CROTTY LAB IDENTIFIED A PAIR OF SIGNALS THAT GOVERN THE FATE OF T FOLLICULAR HELPER CELLS. FOLLICULAR HELPER T CELLS (TFH CELLS), A RARE TYPE OF IMMUNE CELL THAT IS ESSENTIAL FOR INDUCING A STRONG AND LASTING ANTIBODY RESPONSE TO VIRUSES AND OTHER MICROBES, HAVE GARNERED INTENSE INTEREST IN RECENT YEARS BUT THE MOLECULAR SIGNALS THAT DRIVE THEIR DIFFERENTIATION HAD REMAINED UNCLEAR. THE RESEARCHERS FINDING HOLDS GREAT PROMISE FOR IMPROVED VACCINE DESIGN AND MAY LEAD TO NEW TREATMENTS FOR IMMUNE DISORDERS AND POSSIBLY EVEN CANCER. (PUBLISHED IN NATURE IMMUNOLOGY, JULY 2016)THE SETTE LAB IDENTIFIED A UNIQUE SUBSET OF HELPER T CELLS THAT APPEARS TO PLAY AN IMPORTANT PROTECTIVE ROLE IN CONTROLLING DENGUE VIRUS INFECTIONS. THE FINDINGS SUPPORT THE NOTION THAT A SUCCESSFUL DENGUE VACCINE NEEDS TO INDUCE A STRONG T CELL RESPONSE IN ADDITION TO HIGH ANTIBODY TITERS, THE YARDSTICK AGAINST WHICH THE PROMISE OF VACCINE CANDIDATES HAS TRADITIONALLY BEEN MEASURED. (PUBLISHED IN THE PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, AUGUST 2015)THE HEDRICK LAB DISCOVERED THAT A SUBPOPULATION OF WHITE BLOOD CELLS GUARDS AGAINST TUMOR LUNG METASTASIS, MAKING IT THE FIRST STUDY TO SHOW THAT THAT PATROLLING MONOCYTES DIRECTLY BLOCK LUNG METASTASIS, FINDINGS THAT COULD SUGGEST FUTURE IMMUNOTHERAPIES TO TREAT AN EXTRAORDINARILY LETHAL CANCER. HEDRICK AND HER TEAM SUCCESSFULLY TRACKED THE WANDERINGS OF THESE CELLS IN THE LUNG VASCULATURE, FILMED THEM PURSUING INVADING TUMOR CELLS, AND EMPLOYED A MOUSE MODEL THAT THEY DEVELOPED TO DEMONSTRATE HOW EFFECTIVE THIS PURSUIT IS IN A LIVING ANIMAL. (PUBLISHED IN SCIENCE, OCTOBER 2016)THE RAO LAB SHOWED THAT TET PROTEINS PLAY AN INTEGRAL PART IN MAINTAINING GENOME INTEGRITY. MEMBERS OF THE TET (SHORT FOR TEN-ELEVEN TRANSLOCATION) FAMILY HAVE BEEN KNOWN TO FUNCTION AS TUMOR SUPPRESSORS FOR MANY YEARS, BUT HOW THEY KEEP A LID ON THE UNCONTROLLED CELL PROLIFERATION OF CANCER CELLS HAD REMAINED UNCERTAIN. NOW, RAO AND HER DEMONSTRATE THAT TET PROTEINS ARE REQUIRED TO MAINTAIN GENOME INSTABILITY AND COLLECTIVELY CONSTITUTE A MAJOR CLASS OF TUMOR SUPPRESSORS. (PUBLISHED IN NATURE COMMUNICATIONS, DECEMBER 2015)TESTIFYING TO THE HIGH LEVEL OF ACHIEVEMENT TAKING PLACE AT THE INSTITUTE ARE THE AWARDS AND HONORS INSTITUTE SCIENTISTS RECEIVED IN 2015:DR. MITCHELL KRONENBERG, PRESIDENT AND CHIEF SCIENTIFIC OF OFFICER OF THE LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY, HAS BEEN NAMED A FELLOW OF THE AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE (AAAS). ELECTION AS A AAAS FELLOW IS AN HONOR BESTOWED UPON AAAS MEMBERS BY THEIR PEERS FOR SCIENTIFICALLY OR SOCIALLY DISTINGUISHED EFFORTS TO ADVANCE SCIENCE OR ITS APPLICATIONS. DR. KRONENBERG WAS RECOGNIZED FOR HIS DISTINGUISHED CONTRIBUTIONS TO UNDERSTANDING T LYMPHOCYTE BIOLOGY, PARTICULARLY ANALYSIS OF ANTI-BACTERIAL IMMUNE RESPONSES, NKT CELLS, AND TISSUE RESIDENT T CELLS IN THE INTESTINAL MUCOSA. IN ADDITION, IN 2015 THE INSTITUTE SAW CONTINUED ADVANCEMENT OF ITS RESEARCH DISCOVERIES BY INDUSTRY PARTNERS IN THE PHARMACEUTICAL PIPELINE, INCLUDING THERAPIES FOR SICKLE CELL ANEMIA, AS WELL AS FOR PSORIASIS AND ORGAN TRANSPLANT ENTERING PHASE II CLINICAL TRIALS. THE INSTITUTE ALSO FORGED A NUMBER OF NEW RESEARCH COLLABORATIONS WITH BOTH LARGE AND EMERGING PHARMACEUTICAL COMPANIES TOWARDS THE DEVELOPMENT OF NEW THERAPEUTICS AND DIAGNOSTICS IN THE AREAS OF INFECTIOUS DISEASE, ALLERGY AND ASTHMA, AUTOIMMUNITY, AND ONCOLOGY. THESE RELATIONSHIPS GREATLY AID THE TRANSLATION OF LJI EXPERTISE AND RESEARCH FINDINGS TOWARD THE DETECTION, PREVENTION, AND TREATMENT OF A GREAT BREADTH OF HUMAN DISEASES. COMPETITIVE RESEARCH GRANT FUNDING & RESEARCH AWARDS & DISTINCTIONSTHE ABILITY OF LA JOLLA INSTITUTE SCIENTISTS TO RECEIVE INCREASING NUMBERS OF COMPETITIVELY AWARDED RESEARCH GRANTS ATTESTS TO THE HIGH LEVEL OF RESEARCH PRODUCTIVITY PRESENT AT THE INSTITUTE. DURING 2015, LJI SCIENTISTS WORKED WITH THE SUPPORT OF 121 GRANTS AND FELLOWSHIPS FROM THE NATIONAL INSTITUTES OF HEALTH, THE INTERNATIONAL AIDS VACCINE INITIATIVE, THE JUVENILE DIABETES RESEARCH FOUNDATION, THE LIFE SCIENCES RESEARCH FOUNDATION, THE PEW CHARITABLE TRUST, THE JAN COFFIN CHILDS MEMORIAL FUND FOR MEDICAL RESEARCH, THE AMERICAN HEART ASSOCIATION, THE AMERICAN DIABETES ASSOCIATION, THE CANCER RESEARCH INSTITUTE, THE MELANOMA RESEARCH ALLIANCE FOUNDATION, THE CROHN'S AND COLITIS FOUNDATION OF AMERICA, THE OKLAHOMA MEDICAL RESEARCH FOUNDATION, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, THE NATIONAL SCIENCE FOUNDATION, THE ARTHRITIS NATIONAL RESEARCH FOUNDATION, THE TRASHER RESEARCH FUND AND THE A.P. GIANNINI. NOTABLY, IN 2015, AN TEAM LED BY LJI INVESTIGATOR ALESSANDRO SETTE, PH.D., WAS SELECTED AS ONE OF FOUR RECIPIENTS OF A HUMAN IMMUNE PROFILING CONSORTIUM (HIPC) GRANT TOTALING $ 18 MILLION. WITH THIS PRESTIGIOUS GRANT, THE LJI TEAM WILL CHARACTERIZE THE IMMUNE RESPONSE TO DENGUE VIRUS (DENV) AND MYCOBACTERIUM TUBERCULOSIS (TB), BOTH OF WHICH REPRESENT MAJOR GLOBAL HEALTH CHALLENGES. THE PRESTIGIOUS HIPC GRANT AWARD IS A TESTAMENT TO THE CALIBER OF LJI SCIENTISTS AND VALIDATES THEIR SUSTAINED EFFORTS TO FACILITATE VACCINE DEVELOPMENT AND PROVIDES THEM WITH THE OPPORTUNITY TO UNLEASH THE FULL FORCE OF THEIR COLLECTIVE SCIENTIFIC EXPERTISE AND TECHNOLOGICAL CAPABILITIES TO TRACE THE ELEMENTS THAT MAKE UP AN EFFECTIVE IMMUNE RESPONSE.WITH NEW AND RECURRING GRANT SUPPORT, THE INSTITUTE RECEIVED MORE THAN $42 MILLION IN RESEARCH FUNDING IN 2015, WHICH IS SUPPLEMENTED BY CORPORATE FUNDING SOURCES AS WELL AS PHILANTHROPIC SUPPORT. 46703067 1 1 0 1 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 1 94 0 1 399 1 1 1 0 0 0 0 0 0 0 0 0 0 X 21 20 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 CA IL NJ NY X JENNIFER KEYES 8587526500 9420 ATHENA CIRCLE LA JOLLA CA 920371387 MITCHELL KRONENBERG PHD PRESIDENT/CSO 40.00 X X 458941 0 56940 PAMELA W BLAKELY DIRECTOR 2.00 X 0 0 0 ANTHONY CARR DIRECTOR 2.00 X 0 0 0 DAVID DOMINGUEZ DIRECTOR 2.00 X 0 0 0 ROBERT C DYNES PHD DIRECTOR 2.00 X 0 0 0 LEROY HOOD MD PHD DIRECTOR 2.00 X 0 0 0 SERGIO JINICH DIRECTOR 2.00 X 0 0 0 RICHARD K KORNFELD DIRECTOR 2.00 X 0 0 0 JOHN E MAJOR DIRECTOR 2.00 X 0 0 0 TOSHIFUMI MIKAYAMA PHD DIRECTOR 2.00 X 0 0 0 GAIL K NAUGHTON PHD DIRECTOR 2.00 X 0 0 0 TINA S NOVA PHD DIRECTOR (THROUGH 06/02/2015) 2.00 X 0 0 0 DAVID A PERKINS DIRECTOR 2.00 X 0 0 0 GENE W RAY PHD DIRECTOR (THROUGH 07/01/2015) 2.00 X 0 0 0 RHONDA F RHYNE DIRECTOR 2.00 X 0 0 0 FRED WASSERMAN DRPH DIRECTOR 2.00 X 0 0 0 DAVID R WEBB PHD DIRECTOR 2.00 X 0 0 0 HERBERT A WERTHEIM OK DSC DIRECTOR 2.00 X 0 0 0 TIMOTHY J WOLLAEGER DIRECTOR (THROUGH 11/15/2015) 2.00 X 0 0 0 ERIC V ZWISLER DIRECTOR 2.00 X 0 0 0 KRISTINE CHARTON JD DIRECTOR 2.00 X 0 0 0 LARRY S SPITCAUFSKY DIRECTOR 2.00 X 0 0 0 HUNT PETTIT DIRECTOR 2.00 X 0 0 0 RICHARD S BODMAN DIRECTOR 2.00 X 0 0 0 JENNIFER K KEYES CFO 40.00 X 149448 0 18940 STEPHEN WILSON EVP, CHIEF ADMINISTRATIVE OFFICER 40.00 X 294138 0 55922 AMNON ALTMAN DIR, SCIENTIFIC AFFAIRS 40.00 X 333854 0 61407 STEPHEN P SCHOENBERGER PROFESSOR 40.00 X 288192 0 66696 ALESSANDRO SETTE CENTER HEAD/DIVISION HEAD/PROFESSOR 40.00 X 335396 0 66696 JOEL LINDEN PROFESSOR 40.00 X 286834 0 47306 KLAUS LEY DIVISION HEAD/PROFESSOR 40.00 X 324973 0 49028 HILDE CHEROUTRE DIVISION HEAD/PROFESSOR 40.00 X 260285 0 48040 2732061 0 470975 41 0 1 0 PILLSBURY WINTHROP SHAW PITTMAN LLP PO BOX 742262 LOS ANGELES CA 900742262 PATENT RELATED 144988 1 100000 32365201 23194951 55660152 CONSORTIUM REVENUE 900099 5213453 5213453 5213453 206851 206851 67280 67280 4428961 4700965 -272004 -272004 -272004 OTHER INCOME 900099 562688 562688 BUILDING MANAGEMENT 561700 83170 83170 TECHNICAL SERVICES 541900 36095 36095 681953 61557685 5213453 119265 564815 3000 3000 1429590 1258039 145174 26377 18920904 16648088 2251648 21168 1940168 1744017 194017 2134 2385653 2077781 301103 6769 1389379 1248913 138938 1528 290524 248355 42169 190627 190627 1185 1185 9405 9405 199407 199407 207396 9210 197696 490 165947 105694 36492 23761 986113 295163 686423 4527 6352915 5740171 612744 497213 425099 31601 40513 178995 146778 29163 3054 2020752 2020752 191296 187281 4015 LAB SUPPLIES & SVCS 8245061 8218661 26400 CONSORTIUMS 5312203 5312203 PAGE AND MANUSCRIPTS CO 1069659 472094 524421 73144 MINOR EQUIPMENT 709254 541768 167486 119265 119265 52815911 46703067 5899974 212870 2267 2267 7606147 6369621 7894492 16253586 500108 433509 606318 396004 22696938 16195612 8205346 6501326 2846426 6841213 0 0 27661104 36797526 8832162 9357485 1251798 1121123 10083960 10478608 X 16820402 25562176 756742 756742 17577144 26318918 27661104 36797526 8741774 0 X 0 1 X 1 1 1 X UCSD MEDICAL CENTER SAN DIEGO CA RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 0 0 0 0 0 0 0 1 1185 1185 0 0 0 PART II-B, LINE 1: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY IS A MEMBER OF THE ASSOCIATION OF INDEPENDENT RESEARCH INSTITUTES, CALIFORNIA HEALTHCARE INSTITUTE AND RESEARCH! AMERICA. THESE ORGANIZATIONS DESIGNATE A PORTION OF THE DUES THEY RECEIVE FOR LOBBYING ACTIVITIES. 6225024 2684672 3540352 16292876 13365435 2927441 179038 145505 33533 6501326 61438420 0 61438420 119265 119265 61557685 52696646 0 52696646 119265 119265 52815911 PART XI, LINE 4B - OTHER ADJUSTMENTS: EXPENSES NETTED AGAINST REVENUE ON AUDIT FINANCIAL STATEMENTS 119,265. PART XII, LINE 4B - OTHER ADJUSTMENTS: EXPENSES NETTED AGAINST REVENUE ON AUDIT FINANCIAL STATEMENTS 119,265. SOUTH ASIA SUBCONTRACTS 117773 EUROPE (INCLUDING ICELAND AND GREENLAND) SUBCONTRACTS 194844 0 0 0 0 0 0 312617 0 312617 0 0 0 0 0 0 X X X X 0 0 0 0 0 0 0 0 0 MITCHELL KRONENBERG PHD PRESIDENT/CSO 454178 0 0 0 4763 0 39750 0 17190 0 515881 0 0 0 JENNIFER K KEYES CFO 148873 0 0 0 575 0 9864 0 9076 0 168388 0 0 0 STEPHEN WILSON EVP, CHIEF ADMINISTRATIVE OFFICER 275241 0 0 0 18897 0 39750 0 16172 0 350060 0 0 0 AMNON ALTMAN DIR, SCIENTIFIC AFFAIRS 300249 0 1602 0 32003 0 39750 0 21657 0 395261 0 0 0 STEPHEN P SCHOENBERGER PROFESSOR 261460 0 0 0 26732 0 39750 0 26946 0 354888 0 0 0 ALESSANDRO SETTE CENTER HEAD/DIVISION HEAD/PROFESSOR 314151 0 0 0 21245 0 39750 0 26946 0 402092 0 0 0 JOEL LINDEN PROFESSOR 282340 0 0 0 4494 0 39750 0 7556 0 334140 0 0 0 KLAUS LEY DIVISION HEAD/PROFESSOR 290822 0 0 0 34151 0 39750 0 9278 0 374001 0 0 0 HILDE CHEROUTRE DIVISION HEAD/PROFESSOR 257468 0 0 0 2817 0 38744 0 9296 0 308325 0 0 0 SEE PART V 0 SCH L, PART IV, BUSINESS TRANSACTIONS INVOLVING INTERESTED PERSONS: (A) NAME OF PERSON: HILDE CHEROUTRE(B) RELATIONSHIP BETWEEN INTERESTED PERSON AND ORGANIZATION: SPOUSE OF PRESIDENT AND CSO (C) AMOUNT OF TRANSACTION $257,468(D) DESCRIPTION OF TRANSACTION: FULL TIME EMPLOYEE(E) SHARING OF ORGANIZATION REVENUES? = NO(A) NAME OF PERSON: KYOWA HAKKO KIRIN CALIFORNIA INC. ("KKC")(B) RELATIONSHIP BETWEEN INTERESTED PERSON AND ORGANIZATION:KKC IS A SUBSTANTIAL CONTRIBUTOR TO THE ORGANIZATION(C) AMOUNT OF TRANSACTION $4,287,884(D) DESCRIPTION OF TRANSACTION:RESEARCH FUNDING, FACILITY RENT, COST REIMBURSEMENTS (E) SHARING OF ORGANIZATION REVENUES? = NO FORM 990, PART VI, SECTION B, LINE 11 IN ACCORDANCE WITH WRITTEN INSTITUTE POLICY, A DRAFT OF FORM 990 IS PROVIDED TO ALL BOARD MEMBERS FOR THEIR REVIEW AND COMMENT PRIOR TO FILING THE RETURN. COMMENTS AND SUGGESTED CHANGES TO THE DRAFT ARE INCORPORATED INTO THE FINAL VERSION OF FORM 990. FORM 990, PART VI, SECTION B, LINE 12C THE INSTITUTE ADMINISTERS THREE SEPARATE CONFLICT OF INTEREST POLICIES APPLYING TO 1) THE BOARD OF DIRECTORS, 2) FACULTY AND SENIOR ADMINISTRATION, AND 3) AN INVESTIGATOR FINANCIAL CONFLICT OF INTEREST POLICY REQUIRED UNDER NATIONAL INSTITUTES OF HEALTH REGULATIONS. THE INSTITUTE REGULARLY AND CONSISTENTLY MONITORS AND ENFORCES THESE POLICIES IN ACCORDANCE WITH WRITTEN PROCEDURES, WHICH INCLUDE THE COMPLETION OF DISCLOSURE FORMS BY COVERED INDIVIDUALS, EVALUATION OF COMPLETED FORMS BY A DESIGNATED CONFLICT REVIEW OFFICER, AND AS NECESSARY, FURTHER EVALUATION AND DETERMINATION BY A DESIGNATED CONFLICT REVIEW COMMITTEE. IF A CONFLICT IS DETERMINED, A MANAGEMENT PLAN IS DESIGNED AND MONITORED FOR THE SPECIFIC SITUATION. SUCH PLAN MAY REQUIRE THE COVERED INDIVIDUAL TO ELIMINATE THE CONFLICT. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION DECISIONS FOR THE INSTITUTE'S CEO AND OTHER KEY EMPLOYEES ARE MADE ANNUALLY. ADJUSTMENTS, IF ANY, TYPICALLY TAKE EFFECT ON A JANUARY 1ST CYCLE. FOR THESE PURPOSES, THE INSTITUTE'S HUMAN RESOURCES DEPARTMENT OBTAINS RELEVANT MARKET COMPARABILITY DATA FOR EACH POSITION ON AN ANNUAL BASIS. THE INSTITUTE ALSO PERIODICALLY ENGAGES AN INDEPENDENT COMPENSATION CONSULTING FIRM TO PERFORM COMPENSATION STUDIES FOR KEY INDIVIDUALS AND TO EVALUATE THE INSTITUTE'S EXECUTIVE COMPENSATION AND BENEFITS PROGRAMS FOR REASONABLENESS. IN ACCORDANCE WITH ITS CHARTER, THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS REVIEWS AND DISCUSSES THIS INFORMATION, AND THE PERFORMANCE OF THE INSTITUTE'S CEO AND KEY EMPLOYEES, AND FORMULATES RECOMMENDED COMPENSATION ACTIONS TO THE FULL BOARD OF DIRECTORS. THE BOARD OF DIRECTORS REVIEWS THESE RECOMMENDATIONS AND RELATED INFORMATION IN DECIDING COMPENSATION LEVELS FOR EACH POSITION. FORM 990, PART VI, SECTION C, LINE 19 THE INSTITUTE MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. SUMMARIZED FINANCIAL DATA IS ALSO MADE AVAILABLE AS PART OF THE INSTITUTE'S ANNUAL REPORT, WHICH IS WIDELY DISTRIBUTED, AND CAN BE DOWNLOADED FROM THE INSTITUTE'S WEB SITE.